Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | GPR183 | P32249 | 1/20 | 0.30 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.30 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.30 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9948084 | 1.00 | ALDH1A1 (0.31) | ALDH1A1KDM4EMEN1GAAMAPT | |
| SCHEMBL14831571 | 1.00 | ALDH1A1 (0.31) | ALDH1A1KDM4EMEN1GAAMAPT | |
| SCHEMBL30578939 | 1.00 | ALDH1A1 (0.31) | ALDH1A1KDM4EMEN1GAAMAPT | |
| SCHEMBL26111037 | 1.00 | ALDH1A1 (0.31) | ALDH1A1KDM4EMEN1GAAMAPT | |
| SCHEMBL14831570 | 1.00 | ALDH1A1 (0.31) | ALDH1A1KDM4EMEN1GAAMAPT | |
| SCHEMBL6183766 | 1.00 | ALDH1A1 (0.31) | ALDH1A1KDM4EMEN1GAAMAPT | |
| SCHEMBL20238224 | 0.88 | KDM4E (0.33) | ALDH1A1KDM4EMEN1GAAMAPT | |
| SCHEMBL29416849 | 0.88 | KDM4E (0.33) | ALDH1A1KDM4EMEN1GAAMAPT | |
| SCHEMBL20252588 | 0.88 | KDM4E (0.33) | ALDH1A1KDM4EMEN1GAAMAPT | |
| SCHEMBL30972622 | 0.88 | KDM4E (0.33) | ALDH1A1KDM4EMEN1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023093728-A1 | BRM SELECTIVE DEGRADATION AGENT COMPOUND AND USE THEREOF | 江苏先声药业有限公司 | 2023-06-01 | — | — | WO | disclosed |
| WO-2021004467-A1 | COMPOUND AS PORCUPINE INHIBITOR AND USE THEREOF | 南京明德新药研发有限公司 | 2021-01-14 | — | — | WO | disclosed |
| US-10112931-B2 | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH | NOVARTIS AG (CH) | 2018-10-30 | — | — | US | disclosed |
| US-20180051015-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | NOVARTIS AG (CH) | 2018-02-22 | — | — | US | disclosed |
| EP-2970240-B1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | NOVARTIS AG (CH) | 2018-01-10 | — | — | EP | disclosed |
| EP-2771337-B1 | 3-(PYRIMIDIN-4-YL)-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | NOVARTIS AG (CH) | 2017-08-02 | — | — | EP | disclosed |
| US-9688672-B2 | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH | NOVARTIS AG (CH) | 2017-06-27 | — | — | US | disclosed |
| US-20160318915-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | NOVARTIS AG (CH) | 2016-11-03 | — | — | US | disclosed |
| US-9434719-B2 | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH | NOVARTIS AG (CH) | 2016-09-06 | — | — | US | disclosed |
| EP-2970240-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | Novartis AG (CH) | 2016-01-20 | — | — | EP | disclosed |
| US-8957068-B2 | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH | NOVARTIS AG (CH) | 2015-02-17 | — | — | US | disclosed |
| US-20140275083-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | NOVARTIS AG (CH) | 2014-09-18 | — | — | US | disclosed |
| WO-2014141104-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | NOVARTIS AG (CH) | 2014-09-18 | — | — | WO | disclosed |
| EP-2771337-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | Novartis AG (CH) | 2014-09-03 | — | — | EP | disclosed |
| US-20140235620-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | NOVARTIS AG (CH) | 2014-08-21 | — | — | US | disclosed |
| WO-2013046136-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | NOVARTIS AG (CH) | 2013-04-04 | — | — | WO | disclosed |
| EP-1501787-B1 | N-BIPHENYLMETHYL AMINOCYCLOALKANECARBOXAMIDE DERIVATIVES WITH A SUBSTIITUENT ON THE METHYL USEFUL AS BRADYKININ ANTAGONISTS | MERCK & CO INC (US) | 2005-11-09 | — | — | EP | disclosed |
| US-6919343-B2 | N-biphenyl(substituted methyl) aminocycloalkane-carboxamide derivatives | MERCK & CO., INC. (US) | 2005-07-19 | — | — | US | disclosed |
| US-20050084463-A1 | N-biphenylmethyl aminocycloalkanecarboxamide derivatives with a substiituent on the methyl useful as bradykinin antagonists | WOOD MICHAEL R (US) | 2005-04-21 | — | — | US | disclosed |
| US-20030220375-A1 | N-biphenyl(substituted methyl) aminocycloalkane-carboxamide derivatives | MERCK SHARP & DOHME LLC | 2003-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275083-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | IDH1, IDH3B, IDH3A | ALDH1A1 275/4885KDM4E 366/4885MEN1 2398/4885 |
| US-20180051015-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | IDH1, IDH3B, IDH3A | ALDH1A1 275/4885KDM4E 366/4885MEN1 2398/4885 |
| US-20160318915-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | IDH1, IDH3B, IDH3A | ALDH1A1 275/4885KDM4E 366/4885MEN1 2398/4885 |
| US-20030220375-A1 | N-biphenyl(substituted methyl) aminocycloalkane-carboxamide derivatives | BDKRB1, BDKRB2, CNR2 | ALDH1A1 3175/4885KDM4E 1634/4885MEN1 2380/4885 |
| US-20140235620-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | IDH1, IDH3A, IDH3B | ALDH1A1 325/4885KDM4E 442/4885MEN1 2355/4885 |
| US-20050084463-A1 | N-biphenylmethyl aminocycloalkanecarboxamide derivatives with a substiituent on the methyl useful as bradykinin antagonists | BDKRB1, BDKRB2, CNR2 | ALDH1A1 3872/4885KDM4E 1584/4885MEN1 2884/4885 |
| US-10112931-B2 | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH | IDH1, IDH3B, IDH3A | ALDH1A1 275/4885KDM4E 366/4885MEN1 2398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.